Archived HIV-1 Drug Resistance Mutations: Role of Proviral HIV-1 DNA Genotype for the Management of Virological Responder People Living with HIV

• Published in: Viruses Vol. 16; no. 11; p. 1697
• Main Authors: Campagna, Roberta, Nonne, Chiara, Antonelli, Guido, Turriziani, Ombretta
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.11.2024; MDPI
• Subjects: Anti-HIV Agents - pharmacology; Anti-HIV Agents - therapeutic use; Antiretroviral drugs; Antiretroviral therapy; Antiviral agents; APOBEC; Deoxyribonucleic acid; DNA; DNA GRT; DNA sequencing; DNA, Viral - genetics; Dosage and administration; Drug resistance; Drug Resistance, Viral - genetics; Drug therapy; Genetic aspects; Genotype; Genotype & phenotype; Genotypes; Genotyping; GLP-1 receptor agonists; HIV; HIV Infections - drug therapy; HIV Infections - virology; HIV patients; HIV-1; HIV-1 - drug effects; HIV-1 - genetics; Human immunodeficiency virus; Humans; Infections; Lymphocytes; Mutation; NGS; Patient outcomes; Plasma; Proviruses - drug effects; Proviruses - genetics; reservoir; Review; Sanger sequencing; Success; Viral Load - drug effects; Viremia; Italy; HIV-1; NGS; Sanger sequencing; reservoir; DNA GRT; APOBEC

Despite its effectiveness in controlling plasma viremia, antiretroviral therapy (ART) cannot target proviral DNA, which remains an obstacle to HIV-1 eradication. When treatment is interrupted, the reservoirs can act as a source of viral rebound, highlighting the value of proviral DNA as an additiona...